Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes

JAMA

Volumn 287, Issue 19, 2002, Pages 2542-2551

  Hoerger, Thomas J ^a   Bethke, Albert D ^a   Richter, Anke ^a   Sorensen, Stephen W ^b   Engelgau, Michael ^b   Thompson, Ted ^b   Venkat Narayan, K M ^b   Williamson, David F ^b   Gregg, Edward ^b   Zhang, Ping ^b   Eastman, Richard C ^c   Fuller, John ^d   Gibbons, Claire B ^e   Haffner, Steve ^f   Herman, William H ^g   Howard, Barbara ^h   Ratner, Robert ^h   Orchard, Trevor ⁱ  

^a RTI INTERNATIONAL   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c Cygnus Inc   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e USA   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h MEDSTAR RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; PRAVASTATIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FEMALE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 0037092913     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.19.2542     Document Type: Article

References (46)

1. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988-1994
2. Health care expenses for people with diabetes mellitus, 1992
3. Economic consequences of diabetes mellitus in the US in 1997
4. Heart disease and diabetes
5. Stroke and diabetes
6. Mortality in noninsulin-dependent diabetes
7. Model of complications of NIDDM, I: Model construction and assumptions
8. Model of complications of NIDDM, II: Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
9. The cost-effectiveness of screening for type 2 diabetes
10. Physical and metabolic characteristics of persons with diabetes
11. Forecasting coronary heart disease incidence, mortality, and cost: The coronary heart disease policy model
12. Cardiovascular disease risk profiles
13. The recent decline in mortality from coronary heart disease, 1980-1990
14. Direct medical costs of complications resulting from type 2 diabetes in the US
15. Foot infections in diabetic patients
16. Direct medical costs of coronary artery disease in the United States
17. Lifetime cost of stroke in the United States
18. Trends in Medicare payments in the last year of life
19. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial
20. Quality of life of stroke in younger individuals
21. Secular trends in stroke incidence and mortality
22. Stability of time-tradeoff utilities in survivors of myocardial infarction
23. Variation in patient utilities for outcomes of the management of chronic stable angina
24. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
25. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial
26. Overview of 6 years' therapy of type II diabetes: A progressive disease
27. A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
28. The UK prospective diabetes study
29. Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization
30. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)
31. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes
32. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
33. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
34. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study
35. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels
36. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41)
37. A comprehensive league table of costutility ratios and a sub-table of "panel-worthy" studies